NEWPORT BEACH, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Liolios Group, Inc., a leading strategic financial communications and capital markets advisory firm, has appointed Marek Ciszewski, J.D. as managing director to lead the firm’s expanding life sciences practice.
Ciszewski brings to Liolios more than 25 years of Wall Street experience as a portfolio manager and equity analyst with leading financial institutions. Most recently, he worked at BMO Global Asset Management, one of the world’s largest asset managers, as the global head of healthcare research. His other experience includes Vestor Capital, Nesbitt Burns Securities and Perritt Capital Management.
Throughout his investment career, Ciszewski acquired extensive experience in fundamental security analysis and selection, portfolio management and investment strategy. This was underpinned by his innate curiosity and relentless focus on understanding the various business models in the life sciences industry.
Ciszewski’s understanding of investor relations and capital markets is further complemented by his biopharma industry experience. He has held various senior corporate roles, including vice president of corporate development at Verastem, an oncology-focused biopharmaceutical firm, and head of investor relations and corporate communications at Epirus Biopharmaceuticals, a biosimilars pioneer.
“Marek’s comprehensive knowledge of life sciences, investor relations and capital markets will play an important role in expanding our practice,” said Scott Liolios, company founder and president. “His passion for his craft and unique combination of skills, experience and education make him invaluable to companies both preparing to go public and existing public companies that require deep industry knowledge along with a comprehensive suite of IR services. We look forward to benefiting from Marek’s expertise to expand our presence within the dynamic and growing life sciences sector.”
Ciszewski added: “Liolios is a proven and well-established firm with an impressive roster of clients. The entire Liolios team has done an exceptional job building a world-class advisory platform for both pre-IPO and public companies.
“Over the last decade, there have been seismic changes to the biopharma industry, including unprecedented understanding of disease on the molecular level, which has redefined how and when drug development is funded, potentially approved and commercialized. This includes how and when biopharma firms interact with investors and all stakeholders along the drug development path.
“My entire spectrum of experience offers biopharma clients the insight, understanding, and guidance to navigate, differentiate and, ultimately, succeed in the rapidly evolving life sciences industry.”
Ciszewski received a Juris Doctor degree from Chicago-Kent School of Law and a Bachelor of Science in Economics and Finance from DePaul University. He will be based out of Liolios’ Newport Beach headquarters.
About Liolios Group
Liolios is a comprehensive financial communications firm specializing in small- to mid-cap companies. The firm aims to deliver superior performance in corporate messaging and positioning, capital markets advisory, investor awareness and capital formation. Founded in 1999, Liolios executives have extensive experience in finance and investments and represent public and private companies in a wide range of industries, including technology, digital media, consumer/internet retail, healthcare/life sciences, natural resources, financial services and business services. For more information about Liolios, please visit www.liolios.com.